Interactions between tenofovir and nevirapine in CD4+ T cells and: Monocyte-derived macrophages restrict their intracellular accumulation

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2545-2549

  Liptrott, N J ^a   Curley, P ^a   Moss, D ^a   Back, D J ^a   Khoo, S H ^a   Owen, A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Drug drug interactions; Hiv; Influx drug transporters

Indexed keywords

NEVIRAPINE; TENOFOVIR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; DRUG ACCUMULATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL;

DRUG-DRUG INTERACTIONS; HIV; INFLUX DRUG TRANSPORTERS;

ADENINE; ANTI-HIV AGENTS; BLOOD DONORS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; MACROPHAGES; NEVIRAPINE; ORGANOPHOSPHONATES;

EID: 84886281935     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt225     Document Type: Article

References (16)

1. Zhang L, Strong JM, Qiu W et al. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 2006; 3: 62-9.
2. Liptrott NJ, Penny M, Bray PG et al. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol 2009; 156: 497-508.
3. Bleasby K, Castle JC, Roberts CJ et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006; 36: 963-88.
4. Bazzoli C, Jullien V, Le Tiec C et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 2010; 49: 17-45.
5. Uwai Y, Ida H, Tsuji Y et al. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 2007; 24: 811-5.
6. Hartkoorn RC, Kwan WS, Shallcross V et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20: 112-20.
7. Liptrott NJ, Pushpakom S, Wyen C et al. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet Genomics 2012; 22: 10-9.
8. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 2011; 204: 145-53.
9. Weiss J, Rose J, Storch CH et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007; 59: 238-45.
10. Storch CH, Ehehalt R, Haefeli WEet al. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 2007; 323: 257-64.
11. Weiss J, Theile D, Ketabi-Kiyanvash N et al. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and nonnucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007; 35: 340-4.
12. Pruvost A, Negredo E, Theodoro F et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother 2009; 53: 1937-43.
13. Clotet B. Once-daily dosing of nevirapine in HAART. J Antimicrob Chemother 2008; 61: 13-6.
14. Droste JA, Kearney BP, Hekster YA et al. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41: 37-43.
15. Redfield RR, Morrow JS. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine. Clin Infect Dis 2008; 47: 984-5.
16. Skazik C, Heise R, Bostanci O et al. Differential expression of influx and efflux transport proteins in human antigen presenting cells. Exp Dermatol 2008; 17: 739-47.